Database analysis highlights real-world dosing patterns in patients with Crohn's disease, indicating important trends in biologic therapies.
Introduction: Dose escalation is a common strategy to address inadequate or lost response in patients (pts) with Crohn's disease (CD); dose escalations or alternative dosing regimens are permitted in certain cases by the Summary of Product Characteristics (SmPC) of various biologic treatments. Given lack of recent data, we aimed to evaluate real-world data in pts with moderately to severely active CD in Germany to identify and characterize real-world dosing and escalation patterns for advanced biologic therapies.
No takes yet. Share an insight, caveat, or question.
Rößler et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: